Teradyne (TER) is going to go down as another example in my book of how you shouldn't underestimate companies holding a hot hand. While it has been some time since the shares have been conventionally cheap, the company has continued to exceed expectations on a combination of increased testing complexity, growth in key markets, and market share growth with new products.
Surprising to me is that the shares have actually lagged the SOX a bit since my last update. The outperformance on a trailing one-year basis is still meaningful though, and Teradyne bounced back